FedEx has announced that its hub facilities at Guangzhou Baiyun International Airport in China and Kansai International Airport in Japan have received the "CEIV Pharma certification." This certification, provided by the International Air Transport Association (IATA), ensures high standards for the air transport and handling of sensitive healthcare products such as pharmaceuticals and vaccines. The certification reflects FedEx's commitment to quality and compliance in pharmaceutical logistics.
Kawal Preet, President of FedEx Asia Pacific, stated: "The healthcare industry's innovation requires smarter, faster, and more resilient supply chains. The Asia-Pacific region is rapidly emerging as a global hub for clinical trials and biopharmaceutical manufacturing. There is an increasing need for logistics that ensure safety, regulatory compliance, and leverage technology. Our track record and expertise in providing intelligent cold chain solutions help maintain product quality, regulatory adherence, and peace of mind for our customers. By combining AI-powered logistics technology with real-time monitoring across our global network, FedEx supports life sciences companies in advancing next-generation medical innovations with speed, scale, and reliability."
The pharmaceutical logistics market in the Asia-Pacific region is projected to grow from $163 billion in 2025 to $225 billion by 2030 with a compound annual growth rate (CAGR) of 6.68%. The region accounts for about 50% of global clinical trials and plays a critical role in global pharmaceutical research and development. Consistent temperature-controlled services are essential for ensuring product efficacy.